This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Controlled, Double-Blind Comparison

Baron Shopsin, MD; Helmfried Klein, MD; Michele Aaronsom, RN; Maria Collora

Arch Gen Psychiatry. 1979;36(6):657-664.

Abstract
• Clozapine is a unique compound belonging to a relatively new group of antipsychotic agents, the dibenzazepines. To our knowledge, the present study represents the first double-blind, controlled comparison recorded in the United States. The data suggest that clozapine in the present population of newly admitted, acutely psychotic schizophrenic individuals, and in the doses employed, was more effective in overall improvement response, discharge rate, and ameliorating discrete symptoms across the different objective rating scales used than was chlorpromazine (Thorazine) hydrochloride. Placebo was ineffective. Unlike chlorpromazine, no extrapyramidal reactions occurred in those patients ingesting clozapine. Clozapine was also beneficial in reversing abnormal involuntary motor movements. It is an excellent anxiolytic and hypnotic agent. Sedation, hypotension, and hypersalivation are among the more common side effects observed.

Author Affiliations
From the Neuropsychopharmacology Research Unit, Department of Psychiatry, New York University School of Medicine.

Footnotes
Accepted for publication Sept 20, 1978.

Reprint requests to Neuropsychopharmacology Research Unit, Department of Psychiatry, New York University School of Medicine, New York NY 10016 (Dr Shopsin).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The history of clozapine and its emergence in the US market: a review and analysis.
Crilly
History of Psychiatry 2007;18:39-60.
ABSTRACT  

Health Promotion in Persons with Schizophrenia: Atypical Medications
Beebe
J Am Psychiatr Nurses Assoc 2003;9:115-122.
ABSTRACT  

A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis et al.
Arch Gen Psychiatry 2003;60:553-564.
ABSTRACT | FULL TEXT  

Evidence of Clozapine's Effectiveness in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Trials
Wahlbeck et al.
Am. J. Psychiatry 1999;156:990-999.
ABSTRACT | FULL TEXT  

Effect of Neuroleptic Medication on Cerebrospinal Fluid Monoamine Metabolite Concentrations in Schizophrenia: Serotonin-Dopamine Interactions as a Target for Treatment
Kahn et al.
Arch Gen Psychiatry 1993;50:599-605.
ABSTRACT  

m-Chlorophenylpiperazine Effects in Neuroleptic-Free Schizophrenic Patients: Evidence Implicating Serotonergic Systems in the Positive Symptoms of Schizophrenia
Krystal et al.
Arch Gen Psychiatry 1993;50:624-635.
ABSTRACT  

Clinical and Biologic Response to Clozapine in Patients With Schizophrenia: Crossover Comparison With Fluphenazine
Pickar et al.
Arch Gen Psychiatry 1992;49:345-353.
ABSTRACT  

Reduction of dyskinesias and psychiatric disability with clozapine over different time courses
Moore et al.
J Psychopharmacol 1992;6:514-518.
ABSTRACT  

Who Should Receive Clozapine?
Marder and Van Putten
Arch Gen Psychiatry 1988;45:865-867.
ABSTRACT  

Clozapine and Tardive Dyskinesia
Singer
Arch Gen Psychiatry 1983;40:347-347.
ABSTRACT  

Hyperactivity: Symptom Complex or Complex Symptom?
Levine and Oberklaid
Arch Pediatr Adolesc Med 1980;134:409-414.
ABSTRACT